Market Research Reports Search Engine

Meager as the growth may look, it is important to note that the asthma therapeutics market is on the verge of witnessing widespread generic erosion. Patent expirations are expected to eat into the revenues of blockbuster drugs such as Advair (fluticasone propionate/salmeterol xinafoate), Xolair (omalizumab), and Symbicort (budesonide/formoterol fumarate). This sea change in the global asthma therapeutics market will be brought about by the entry of new players as well as the growing pervasiveness of asthma itself. Browse Full Report with TOC : http://www.mrrse.com/asthma-therapeutics-market The report notes that there is unparalleled industry interest in monoclonal antibodies and biologics, with the former enjoying more attention within the indication. Clinical trials have shown encouraging results for new monoclonal antibodies; some of these include: Lebrikizumab, mepolizumab, dupilumab target Interleukins (IL), and reslizumab.  These molecules are seen to be bene...

The research report identifies the key driving factors of the asthma therapeutics market as the rising environmental pollution that adversely affects the respiratory system of the human body, causing asthma and other respiratory diseases. Rapidly growing industrialization and globalization have led to an imbalance in the environmental constitution. One of the most conspicuous trends in this market is the adoption of a combination of therapies for the treatment of asthma patients. This technique can further help asthma patients by controlling inflammation caused in the respiratory tract. However, the biggest challenge faced by the drug producers is the etiology of respiratory diseases owing to which developing the remedy becomes a tough job. Browse Full Report With TOC : http://www.mrrse.com/reports/asthma-therapeutics-market Some of the key players of the global asthma therapeutics market are GlaxoSmithKline plc, Merck & Co. Inc., Novartis AG, AstraZeneca plc, and F. Hoffmann-L...